Table 1.
Percent susceptibility of drug-resistant Gram-positive MRSA and Gram-negative MBL producers to combinations of Exo-MS and DFO-B with antibiotics by the disc diffusion method
| Pathogen | Standard antibiotics | Isolates susceptible to combination of Exo-MS + antibiotic (%) | Isolates susceptible to combination of DFO-B + antibiotic (%) |
|---|---|---|---|
| MRSA (n=20) | Ampicillin (0.01 mg) | 15 (75) | 10 (50) |
| Cefdinir (0.005 mg) | 5 (33) | 1 (05) | |
| MBL-producing Pseudomonas aeruginosa (n=15) | Ampicillin (0.01 mg) | 4 (27) | 5 (33) |
| Imipenem (0.01 mg) | 7 (47) | 8 (53) | |
| Meropenem (0.01 mg) | 9 (60) | 6 (40) | |
| MBL-producing Acinetobacter baumannii (n=15) | Ampicillin (0.01 mg) | 7 (47) | 6 (40) |
| Imipenem (0.01 mg) | 7 (47) | 8 (53) | |
| Meropenem (0.01 mg) | 10 (67) | 10 (67) |
Abbreviations: DFO-B, deferoxamine-B; Exo-MS, exochelin-MS; MBL, metallo-β-lactamase; MRSA, methicillin-resistant Staphylococcus aureus.